[Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma]

Area of Science:

• Biotechnology and Molecular Oncology

Background:

• Gene errors encode proteins, particularly kinase enzymes, crucial for tumor development.
• Epidermal growth factor receptor (EGFR) is a key cell surface receptor involved in tumor progression.
• Activating mutations in EGFR's tyrosine kinase domain are linked to lung adenocarcinoma sensitivity to targeted therapies.

Purpose of the Study:

• To highlight the role of gene mutations in cancer therapy.
• To emphasize the significance of identifying specific molecular targets for effective treatment.

Main Methods:

• Leveraging biotechnological advancements for gene error identification.
• Observing the sensitivity of lung adenocarcinoma cells with EGFR mutations to anti-EGFR compounds.

Main Results:

• Biotechnology facilitates the identification of gene errors driving tumor growth.
• Lung adenocarcinoma cells with specific EGFR mutations demonstrate high sensitivity to anti-EGFR drugs.
• Mutation identification is the foundation for effective targeted cancer therapy.

Conclusions:

• Targeted therapies based on molecular diagnostics represent a new era in cancer chemotherapy.
• Identifying EGFR mutations guides therapeutic choices for improved patient outcomes.
• Personalized medicine, guided by molecular targets, is crucial for future tumor treatment.